---
title: PSI vs ProSciento
slug_a: appian
slug_b: prosciento
site: cro
review_signal_gate: closed
canonical_path: /compare/appian/prosciento
generated_by: BioBM Editorial AI
---

# PSI vs ProSciento

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

PSI (appian) is listed for cro. PSI runs full-service Phase 2 and 3 clinical trials with a stated focus on on-time enrollment and over 90% repeat and referral business. Key therapeutic areas include oncology, GI, hematology, cell and gene therapy, neurology, and infectious diseases.

Services: 3. Modalities: 3. Indications: 9. Locations: 1. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in indications (9).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

ProSciento (prosciento) is listed for cro. Specialized CRO focused on metabolic diseases (obesity, diabetes, MASLD/MASH, cardiovascular, chronic kidney disease) with two decades of expertise, a nationwide registry of 180,000+ participants, and full-service clinical development capabilities from Phase 1 through Phase 3.

Services: 5. Modalities: 0. Indications: 3. Locations: 1. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (5).

Review summary: Review summary withheld until site-level review gate opens.